Arcus Biosciences, Inc. (NYSE:RCUS – Get Free Report)’s share price shot up 4.9% during trading on Friday. The company traded as high as $16.08 and last traded at $16.5490. 96,512 shares changed hands during mid-day trading, a decline of 93% from the average daily volume of 1,411,621 shares. The stock had previously closed at $15.78.
Wall Street Analyst Weigh In
Several research firms recently weighed in on RCUS. TD Cowen started coverage on Arcus Biosciences in a research report on Wednesday, September 16th. They set a “buy” rating for the company. JPMorgan Chase & Co. started coverage on Arcus Biosciences in a research report on Wednesday, October 14th. They issued an “overweight” rating and a $41.00 price target on the stock. Citigroup upped their price target on Arcus Biosciences from $45.00 to $50.00 and gave the stock a “buy” rating in a report on Wednesday, October 21st. Truist Financial reduced their price objective on Arcus Biosciences from $41.00 to $40.00 and set a “buy” rating for the company in a research report on Thursday, November 5th. Finally, Wall Street Zen downgraded shares of Arcus Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, October 24th. Twelve analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Arcus Biosciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $39.36.
Check Out Our Latest Analysis on Arcus Biosciences
Arcus Biosciences Stock Performance
Arcus Biosciences (NYSE:RCUS – Get Free Report) last announced its quarterly earnings results on Wednesday, November 4th. The company reported ($1.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.89) by ($0.11). The business had revenue of $9.00 million during the quarter, compared to the consensus estimate of $7.58 million. Arcus Biosciences had a negative net margin of 453.00% and a negative return on equity of 91.65%. The company’s quarterly revenue was down 65.4% compared to the same quarter last year. During the same period last year, the firm earned ($1.27) EPS. As a group, sell-side analysts expect that Arcus Biosciences, Inc. will post -3.49 earnings per share for the current year.
Hedge Funds Weigh In On Arcus Biosciences
Several hedge funds and other institutional investors have recently modified their holdings of RCUS. BlackRock Inc. acquired a new position in Arcus Biosciences during the second quarter worth $506,113,000. Goldman Sachs Group Inc. boosted its stake in shares of Arcus Biosciences by 18.0% in the 3rd quarter. Goldman Sachs Group Inc. now owns 1,637,095 shares of the company’s stock valued at $42,286,000 after purchasing an additional 249,529 shares in the last quarter. Parkman Healthcare Partners LLC bought a new stake in shares of Arcus Biosciences in the 2nd quarter worth about $28,341,000. Aberdeen Group plc grew its holdings in shares of Arcus Biosciences by 62.4% in the 3rd quarter. Aberdeen Group plc now owns 1,056,679 shares of the company’s stock worth $27,294,000 after purchasing an additional 405,967 shares during the last quarter. Finally, Bank of America Corp DE acquired a new stake in shares of Arcus Biosciences during the 2nd quarter worth about $25,759,000. Institutional investors own 92.89% of the company’s stock.
About Arcus Biosciences
Arcus Biosciences is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. Founded in 2015 and headquartered in Hayward, California, the company researches therapies that target immune pathways and other processes involved in tumor growth. Its pipeline consists of investigational medicines, including antibody and small-molecule candidates designed to be used alone or in combination. Arcus’s research has focused on areas such as checkpoint inhibition and the adenosine pathway; its candidates are under clinical development and are not established treatments.
Featured Articles
- Five stocks we like better than Arcus Biosciences
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Arcus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
